

LSU HSC-New Orleans Institutional Biosafety Committee
Ad Hoc Meeting Minutes

Date: Tuesday, November 25, 2025

Time: 10:00 AM -10:24AM

Location: Zoom

Members present:

1. Zea, *IBC Chair*
2. Catling, *IBC Vice Chair*
3. Didier Mejia, *BSO*
4. Aiyar
5. Birke, *Animal Containment*
6. Wang
7. Yue
8. Zabaleta

Members excused:

1. Curran, *Local Non-affiliated Member*
2. Guidry, *Local Non-affiliated Member*
3. Fuselier, Research Compliance Analyst II, IACUC/IBC

Other Individuals in Attendance:

1. Landry, Research Compliance Analyst II, IBC/IACUC

10:01am **Quorum Present**

The IBC has 11 voting members and 6 are required to conduct business

10:02am **Call to Order**

The IBC Chair called the meeting to order

10:03am **Conflicts of Interest**

The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.

10:05am **Full Committee Review of applications subject to NIH Guidelines and our Policies. Continuing IBC oversight required.**

IBC #5011	Development of protective vaccine and antibody as Immunotherapies for Disseminated Candidiasis and MDR infections
PI Name	Xin, Hong
Amendment Overview	<p>This amendment expands the scope of the approved disseminated infection models to include additional medically relevant fungal and bacterial organisms for efficacy testing. In addition to the <i>Candida</i> species currently approved, the protocol will now include <i>Candida tropicalis</i> (ATCC 200956), <i>Candida glabrata</i> (ATCC 200918), <i>Candida auris</i> (CDC AR Bank #0386), and <i>Acinetobacter baumannii</i> (ATCC 17978).</p> <p>These organisms will be incorporated into the existing vaccination, passive antibody treatment, and challenge studies using the same intramuscular immunization schedules, passive antibody</p>

Institutional Biosafety Committee

	<p>treatment regimens, and intravenous challenge routes previously approved. No changes are proposed to the overall experimental design, animal monitoring plans, humane endpoints, or study timelines. The only procedural change is the addition of these specific strains to broaden efficacy testing.</p> <p>All organisms will be handled under BSL-2/ABSL-2 containment with enhanced contact precautions, in accordance with the detailed SOPs submitted to the IBC, including the SOP for cyclophosphamide administration. Biosafety practices remain consistent with current approvals, with no changes other than organism inclusion.</p>
NIH Guidelines Section(s)	III-D-4-b
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, eye goggles, lab coats or disposable gowns, head covers, biosafety cabinet BSL2 rated, and surgical masks. The laboratory will follow EPA List P recommendations for disinfectants effective against <i>Candida auris</i> . All laboratory surfaces, equipment, and biological safety cabinet (BSC) interiors will be decontaminated using EPA-registered sporicidal disinfectants, including Sani-Cloth® Bleach Germicidal Wipes, Oxivir® 1 Wipes and 10% freshly prepared bleach (0.5% sodium hypochlorite) with a minimum contact time of 5–10 minutes when wipes are not suitable. To reduce the risk of aerosol or splash generation, disinfectant wipes will be used as the primary decontamination method, with liquid disinfectants applied only when wipes are not feasible, such as for larger equipment or spill cleanup inside the BSC.
Training	<p>All institutional trainings required are complete for lab staff listed in the registration:</p> <ul style="list-style-type: none"> • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and deficiencies have been corrected.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2+ ABSL-2
IACUC status (if applicable)	Application reviewed and approved
IBC Vote	<p>The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA)</p> <ul style="list-style-type: none"> • Votes: 7/8 MRSA, 1/8 Approve • COI: None reported <p>Following a duly called vote of the committee, this amendment was approved contingent upon submission and approval of the requested revisions by the Primary Reviewer and BSO.</p>

10:24am

Adjournment

The IBC Vice Chair moved to adjourn the meeting at 10:53AM. The next meeting is tentatively scheduled for Wednesday, December 10, 2025, via Zoom.